Fundraising Fox

VintaBio

1 known investors

VintaBio provides viral vector manufacturing for clinical and commercial gene therapies, using a single-stream process (VintaProcess) to produce high-yield, high-purity vectors. It offers end-to-end services from discovery through final delivery for cell and gene therapy developers.

BiotechDeep TechHealthtech

Investors · 1

Decheng CapitalMenlo Park

Funding

SEC filings, press & company announcements

$64M disclosed across 1 round · 2023

Source: company announcements and press reports — follow each round's link for the claim.

In the news

What is Brief History of VintaBio Company? – businessmodelcanvastemplate.combusinessmodelcanvastemplate.com · Jun 2024VintaBio Opens Custom-built Manufacturing Facility in Philadelphia for CGTs | Contract Pharmacontractpharma.com · Apr 2023VintaBio Emerges with $64 Million to Manufacture High Quality Viral Vectors for Cell and Gene Therapies - Global Genesglobalgenes.org · Apr 2023VintaBio, aiming to meet cell and gene therapy manufacturing needs, launches with $64M raisetechnical.ly · Apr 2023VintaBio Unveils $64M to Back Viral Vector Trailblazers Behind the First Approved Cell and Gene Therapiesprnewswire.com · Apr 2023VintaBio, located in Philadelphia Navy Yard, raises $64M in funding - Philadelphia Business Journalbizjournals.com · Apr 2023

Frequently asked questions

What does VintaBio do?
VintaBio provides viral vector manufacturing for clinical and commercial gene therapies, using a single-stream process (VintaProcess) to produce high-yield, high-purity vectors. It offers end-to-end services from discovery through final delivery for cell and gene therapy developers.
Who are VintaBio's investors?
VintaBio's investors include Decheng Capital.
How much funding has VintaBio raised?
VintaBio has disclosed $64M raised across 1 round.